User:Ptcoca/sandbox

Now CTO and Co-founder of Haemostatix Limited, Sarah Middleton has more than 30 years’ experience in blood product and biopharmaceutical development. Products include HyateC, porcine Factor VIII, for the treatment of Haemophilia A and recombinant human albumin, as well as Synthocytes, a prototype platelet substitute. Sarah was previously Chief Scientist at Speywood Laboratories; Director of Clinical, Quality Assurance and Regulatory Affairs at Delta Biotechnology and Project Director at Andaris.